Medeon Biodesign (6499) fair value: what the stock is really worth
As of Nov 17, 2026: fair value (intrinsic value) of Medeon Biodesign stock TWD 50.44, price TWD 67.30, that is 25.1% below the price, quality 49 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Medeon Biodesign
6499 · TWOExpensive (fair value 25% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.
How to read this chart
60‑month range 35.05 TWD – 145.00 TWD · fair‑value band 37.83 TWD – 63.04 TWD · the 67.30 TWD price screens above the 50.44 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.
Every Wednesday you see whether Medeon Biodesign is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States.
Show moreShow less
The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular graft system; PUMA, solution to treat orthopedic extremity injuries; ClickClean, a solution to view throughout laparoscopic surgeries; and AbClose to prevent port site herniation caused by improper closure.
It is engaged in the medical device contract manufacturing; and manufacture and sale of injection molding and components of medical devices. Medeon Biodesign, Inc. was incorporated in 2012 and is based in Taipei, Taiwan.
Stock analysis
Medeon Biodesign (6499) currently trades at 67.30 TWD, while our estimate is 50.44 TWD, 25% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: 37.83 TWD (bear) to 63.04 TWD (bull), the price of 67.30 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Medeon Biodesign reported revenue of 419M TWD in FY2025 versus 69.0M TWD in FY2021, a compound +57.0%/yr. Reported net income was −668M TWD in FY2025.
Key figures
Market cap 6.5B TWD (≈ $198M) Micro · P/S ratio 16.5 · EPS (TTM) −5.96 TWD · Net margin −130% · Return on equity −51.2% · Return on assets (EBIT) −28.2% (5-year average) · Operating margin −132% · Revenue (TTM) 428M TWD.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).
What moves the price
The share trades about 45% below its 52-week high and 21% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at −25%, 6499 screens cheaper than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
6499 screens overvalued: fair value 25% below the price. Compare with Intuitive Surgical, Inc →
Compare Medeon Biodesign with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 199 stocks
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Return on equity by industry
- Quality Score by industry
- Stock screener with 62 metrics
- Undervalued stocks: Taiwanese Stocks
- Valuation of the Taiwan market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Solventum Corporation SOLV | $88.65 | $131.27 | +48% | vs 6499 |
| EssilorLuxottica Société anonyme EL | €184.50 | €196.22 | +6% | vs 6499 |
| Intuitive Surgical, Inc ISRG | $437.75 | $353.90 | −19% | vs 6499 |
| Medline Inc MDLN | $39.17 | $28.59 | −27% | vs 6499 |
| Alcon Inc ALC | CHF 62.14 | CHF 35.08 | −44% | vs 6499 |
| Becton, Dickinson and Company BDX | $216.47 | $97.80 | −55% | vs 6499 |
| Straumann Holding STMN | CHF 108.75 | CHF 45.50 | −58% | vs 6499 |
| West Pharmaceutical Services, Inc WST | $417.80 | $139.22 | −67% | vs 6499 |
| Sartorius Stedim Biotech S.A DIM | €225.20 | €54.82 | −76% | vs 6499 |
| Sartorius Aktiengesellschaft SRT | €226.50 | €46.44 | −80% | vs 6499 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Medeon Biodesign (6499) overvalued or undervalued?
What is the fair value of 6499?
What is the quality score of 6499?
What is the price target for Medeon Biodesign (6499)?
What is the Medeon Biodesign stock forecast for 2026?
What is the revenue of Medeon Biodesign (6499)?
What is the intrinsic value of Medeon Biodesign (6499)?
Is Medeon Biodesign stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 6499?
How much is Medeon Biodesign worth?
What do the bullish and bearish scenarios say about 6499?
How solid is the balance sheet of Medeon Biodesign (6499)?
How far is 6499 from its 52-week high?
Which stocks are comparable to Medeon Biodesign?
Is Medeon Biodesign stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Medeon Biodesign (6499)?
What should I pay attention to with Medeon Biodesign right now?
Key figures of Medeon Biodesign
How large is the market capitalisation of Medeon Biodesign (6499)?
What is the P/S ratio of Medeon Biodesign (6499)?
What are the earnings per share of Medeon Biodesign (6499)?
What is the net margin of Medeon Biodesign (6499)?
What is the return on equity of Medeon Biodesign (6499)?
What is the EBIT return on assets of Medeon Biodesign (6499)?
What is the operating margin of Medeon Biodesign (6499)?
How fast is revenue growing at Medeon Biodesign (6499)?
How much free cash flow does Medeon Biodesign (6499) generate?
Watch Medeon Biodesign in the live analysis
One click puts Medeon Biodesign on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.